CT-P52 (ixekizumab biosimilar) / Celltrion - LARVOL DELTA

A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P52 in Healthy Male Subjects (clinicaltrials.gov) - P1 | N=218 | Completed | Sponsor: Celltrion | Active, not recruiting ➔ Completed | Trial completion date: Jan 2027 ➔ Jul 2026

Trial completion • Trial completion date

A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P52 in Healthy Male Subjects (clinicaltrials.gov) - P1 | N=218 | Active, not recruiting | Sponsor: Celltrion | Not yet recruiting ➔ Active, not recruiting

Enrollment closed

A Study to Compare the Auto-injector and Pre-filled Syringe of CT-P52 in Healthy Male Subjects (clinicaltrials.gov) - P1 | N=218 | Not yet recruiting | Sponsor: Celltrion

New P1 trial

Study to Compare Pharmacokinetics and Safety of CT-P52 and US-licensed Taltz in Healthy Subjects (clinicaltrials.gov) - P1 | N=218 | Active, not recruiting | Sponsor: Celltrion | Recruiting ➔ Active, not recruiting

Enrollment closed